X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease.
Lead Product(s): tRNA Medicine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Alltrna
Deal Size: $109.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 09, 2023
Details:
The company intends to use the net proceeds to fund the completion of the Company’s ongoing Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of moderate psoriasis.
Lead Product(s): EDP2939
Therapeutic Area: Dermatology Product Name: EDP2939
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Evelo Biosciences
Deal Size: $25.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 12, 2023
Details:
The net proceeds will be used to support the development of Empress's proprietary Chemilogics™ product platform which creates potential small molecule medicines and the company's initial pipeline of drug candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Empress Therapeutics
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 21, 2023
Details:
The proceeds will advance Metaphore's MIMiC drug discovery platform and build its pipeline for autoimmune, metabolic or oncology indications. The MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules for therapeutic benefit.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Metaphore Biotechnologies
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 16, 2023
Details:
Under the agreement, Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets with the aim of creating optimized small molecules that lead to novel therapies for unmet medical needs.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Charles River Laboratories International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 16, 2023
Details:
The proceeds of the financing will be used to grow Cellarity’s talent base, strengthen its platform, and advance its pipeline toward the clinic with the development of compounds that have been validated in vitro and in vivo, including in higher species.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Cellarity
Deal Size: $274.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 04, 2022
Details:
The proceeds of the financing will be used to drive further development of Senda’s proprietary programmable medicines platform and advance its first programs into clinical testing. Senda is developing a new class of SendRNA™ medicines.
Lead Product(s): SendRNA Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Senda Biosciences
Deal Size: $123.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 16, 2022
Details:
Net proceeds are expected to be used to advance Syros’ clinical development pipeline including SY-2101, a novel oral form of arsenic trioxide, business development activities, working capital and other general corporate purposes.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Syros Pharmaceuticals
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 05, 2022
Details:
Evelo intends to use the net proceeds from the offering to continue the development of EDP1815 in a Phase 2 trial in atopic dermatitis; prepare to advance EDP1815 in registration trials in psoriasis and, upon receipt of positive Phase 2 data, atopic dermatitis.
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Evelo Biosciences
Deal Size: $79.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 25, 2022
Details:
Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
